Paclitaxel-Bleomycin/Etoposide/Cisplatin vs Bleomycin/Etoposide/Cisplatin in Poor-prognosis Non-seminomatous Germ Cell Tumors (NSGCT) and Unfavorable Tumor Marker Decline
NCT07847190
Summary
GETUG-13 study has prospectively confirmed poor outcomes in advanced germ cell tumors (GCT) patients with unfavorable decrease of tumor markers after 1 cycle of BEP chemotherapy. There is an unmet medical need to improve outcomes in this subset of patients, however the dose-dense regimen proposed in the above-mentioned trial cannot be implemented in routine clinical practice. T-BEP regimen may have advantage over the traditional BEP regimen as first-line therapy for poor-risk GCT Treatment escalation with T-BEP regimen may be an effective and tolerable therapeutic option for advanced GCT patients with unfavorable tumor markers decline.
Eligibility
Inclusion Criteria: * Age ≥16 years; * Evidence of NSGCT based on histologic examination or clinical evidence (high serum HCG or AFP levels - in case of clinical emergency due to bulky disease, therapy can be started without pathological confirmation of the disease); * Testicular, retroperitoneal, or mediastinal primary site; * Disease classified as poor prognosis according to IGCCCG criteria: * Primary mediastinal NSGCT or * Non-pulmonary visceral metastases or * HCG \> 50,000 UI/l, or AFP \> 10,000 ng/ml, or LDH \> 10 times the upper normal value. * No prior chemotherapy; * No concurrent malignancies which may have an impact of anticipated lifespan (ie, malignancies other than basal-cell skin carcinoma, in situ carcinomas, borderline ovarian tumors etc); * Adequate renal function: measured or calculated glomerular filtration rate \> 60 ml/min. * Absolute baseline granulocyte count ≥0.5\*10\^9, platelets ≥100\*10\^9, bilirubin ≤1.5 ULN. * Unfavorable tumor marker decline after 1st cycle of standard BEP chemotherapy calculated according to time to normalization from the K. Fizazi study in JCO 2004. * Signed informed consent before protocol-specific procedures. Exclusion Criteria: * Primary intracranial germ-cell tumors; * Patients with seminomas or dysgerminomas; * Patients with normal range of serum tumor markers before starting treatment; * Patients with favorable tumor markers decline; * Patients infected by the Human Immunodeficiency Virus (HIV); * Patients with contraindications to taxane agents (hypersensitivity to paclitaxel); * Patients who do not fit inclusion criteria.
Conditions2
Interventions5
Related trials
- Electrochemotherapy With Carboplatinum Plus Bleomycin Versus Bleomycin Alone in Vulvar Cancer — IRCCS Azienda Ospedaliero-Universitaria di Bologna
- First Line Chemotherapy for Classical Hodgkin Lymphoma in Russia (HL-Russia-1) — State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia
- TC or BEP in Treating Patients With Malignant Ovarian Germ Cell Tumors — Beihua Kong
- TC or BEP in Treating Patients With Ovarian Malignant Sex Cord-Stromal Tumors — Beihua Kong
- The Effect of Reduced Bleomycin in Electrochemotherapy Treatment — Julie Gehl
- Brentuximab Vedotin in Early Stage Hodgkin Lymphoma — University College, London
- A Phase II Study to Evaluate the Efficacy and Safety of SKB571 in Recurrent or Metastatic HNSCC Participants — Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
- A Phase Ib/II Study of 7MW3711 Combined With JS207 in Advanced Solid Tumors — Mabwell (Shanghai) Bioscience Co., Ltd.
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
NCT07847190